Retatrutide in obstructive sleep apnoea with obesity — evidence extract
The Institute's graded assessment of Retatrutide for obstructive sleep apnoea with obesity, with the contributing trials and the domain-by-domain certainty reasoning.
§1Evidence extract: Obstructive sleep apnoea with obesity
§1.1Question and anchor outcome
- Population
- Recurrent upper-airway obstruction during sleep producing apnoeas and hypopnoeas, graded by the apnoea–hypopnoea index on polysomnography.
- Intervention
- Retatrutide, subcutaneous once weekly
- Comparator
- As used in each contributing trial; reported per trial rather than pooled across comparator types
- Anchor outcome
- Change in apnoea–hypopnoea index (events/hour)
Additional outcomes the Institute extracts for this indication: Proportion achieving disease remission or mild disease; Change in Epworth Sleepiness Scale; Change in systolic blood pressure.
§1.2Contributing trials
Table 1. Trials contributing to the assessment of Retatrutide in obstructive sleep apnoea with obesity.
| Trial | Phase | Design | Randomised | Duration | Year |
|---|---|---|---|---|---|
| TRIUMPH-OSA | 3 | Randomised, double-blind, placebo-controlled | — | 52 weeks | — |
§1.3Certainty assessment
Table 2. Reasoning recorded against each certainty domain.
| Domain | Rating | Reasoning |
|---|---|---|
| Risk of bias | Serious | Contributing trials are sponsor-conducted and one is open-label. |
| Inconsistency | Serious | Direction is consistent; magnitude varies with the intensity of the background intervention. |
| Indirectness | No concern | No serious concern identified in this domain. |
| Imprecision | No concern | No serious concern identified in this domain. |
| Publication bias | Very serious | The evidence base is small, recent and wholly sponsor-generated. |
| Overall rating: Not rated certainty. No certainty rating applies to this document type, or no effect estimate was assessed. | ||
§1.4What this extract does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 · PMID 37366315
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X · PMID 37385280
- Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009 · PMID 30473097
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.